Scholars Central

Conference abstractPublished 27 Oct 2016

Targeting the toxic oligomers of amyloidogenic proteins by self-assembled cyclic D, L-α-peptides: Potential application for Alzheimers and Parkinsons diseases

Authors: Shai Rahimipour, Marina Chemerovski-Glikman, Michal Richman

Bar-Ilan University, Israel

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Protein misfolding and aggregation is the fundamental cause of more than 20 amyloidogenic diseases affecting either the central nervous system or a variety of peripheral tissues. Although peptides and proteins of various sequences can selfassemble into toxic amyloid structures, they share common three-dimensional features that may promote their cross-reaction. Given the significant structural and biochemical similarities between amyloids and the architecture of self-assembled cyclic D, L- Ã?±-peptides, we hypothesized that the latter may bind and stabilize the non-toxic forms of different amyloids, thereby preventing their aggregation into toxic forms. By screening an unbiased library of six-residue cyclic D,L-Ã?± -peptides and optimizing the activity of a lead peptide, we found one cyclic D, L- Ã?± -peptide (CP-2) that interacts strongly with Alzheimer’s disease associated Amyloid beta (AÃ?²) and inhibits its aggregation and toxicity. Further studies including Thioflavin T assays, electron microscopy, and circular dichroism spectroscopy, collectively suggest that CP-2 could also effectively crossinteract with Parkinson’s disease associated Ã?±-synuclein (Ã?±-syn), prevent its aggregation, and remodels its fibrils to non-toxic amorphous species, through an âÂ?Â?off pathwayâÂ? mechanism. NMR studies show that CP-2 interacts with the N-terminal and the non-AÃ?² component region of Ã?±-syn, which are responsible for Ã?±-syn’s membrane interactions and self-assembly, and so changes its conformation. Dot-blot and cell survival assays suggest that CP-2 reduces the amount of toxic Ã?±-syn oligomers and protects PC-12 and SH-SY5Y cells from Ã?±-syn induced toxicity. Moreover, CP-2 permeates cells through endosomes/ lysosomes, co-localizes with intracellular Ã?±-syn and reduces its accumulation and toxicity in neuronal cells over-expressing Ã?±-syn. Our studies suggest that targeting the common structural conformation of amyloids may be a promising approach for developing new therapeutics for amyloidogenic diseases.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Drug Designing: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDrug Designing: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Shai Rahimipour”
  • BylineArticles whose byline prints “Marina Chemerovski-Glikman”
  • BylineArticles whose byline prints “Michal Richman”